Biomarin Pharmaceutical Inc logo

BMRN - Biomarin Pharmaceutical Inc Share Price

$88.27 -0.9  -1.0%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £12.19bn
Enterprise Value £12.29bn
Revenue £1.23bn
Position in Universe 573rd / 6415
Bullish
Bearish
Unlock BMRN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BMRN Revenue Unlock BMRN Revenue

Net Income

BMRN Net Income Unlock BMRN Revenue

Normalised EPS

BMRN Normalised EPS Unlock BMRN Revenue

PE Ratio Range

BMRN PE Ratio Range Unlock BMRN Revenue

Dividend Yield Range

BMRN Dividend Yield Range Unlock BMRN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BMRN EPS Forecasts Unlock BMRN Revenue
Profile Summary

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated October 25, 1996
Public Since July 21, 2009
No. of Shareholders: 44
No. of Employees: 2,849
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite , Nasdaq 100 ,
Exchange NASDAQ Global Select Market
Shares in Issue 179,625,303
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BMRN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BMRN
Upcoming Events for BMRN
Similar to BMRN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.